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Abstract
The post-transcriptional modification of mammalian transcripts in the central nervous system by
adenosine-to-inosine RNA editing is an important mechanism for the generation of molecular
diversity, and serves to regulate protein function through recoding of genomic information. As the
molecular players and an increasing number of edited targets are identified and characterized,
adenosine-to-inosine modification serves as an exquisite mechanism for customizing channel
function within diverse biological niches. Here, we review the mechanisms that could regulate
adenosine-to-inosine RNA editing and the impact of dysregulation in clinical conditions.
Introduction
Nuclear pre-mRNA editing by selective adenosine deami-
nation is catalyzed by a family of enzymes known as Ade-
nosine Deaminases Acting on RNA (ADARs) [1], which
results in a single nucleotide change from adenosine (A)
to inosine (I). A-to-I editing is a dynamic and versatile
post-transcriptional mechanism of single nucleotide
recoding, which could drastically alter both the functional
properties and expression levels of protein-coding
mRNAs, increasing the repertoire of proteins available.
Currently, most of the identified targets of A-to-I RNA
editing are found in the mammalian nervous system, such
as the ion channels and neurotransmitter receptors that
play crucial roles in electrical excitability and signal trans-
duction. Recoding of these proteins by RNA editing pro-
vides an attractive mechanism for customizing specific
channel function within diverse biological niches, and
any dysregulation of the process may contribute to the
pathogenesis of certain diseases. Despite the tremendous
amount of research invested in understanding the effects
of RNA editing, how this activity is dynamically regulated
remains unclear. In this review, we would discuss some
potential mechanisms and factors that could dynamically
regulate this A-to-I modification by ADAR, namely the
expression and activity of ADAR family members via self-
editing, alternative splicing and cross-talk between these
two mechanisms. Environmental cues and other factors
that modulate developmental and activity-dependent
RNA editing will also be examined. In addition, some
consequences of dysregulation in RNA editing in the nerv-
ous system will be discussed with regards to their clinical
relevance.
RNA editing of ion channels and receptors alters their 
function and expression
Ion channels and neurotransmitter receptors in the mam-
malian nervous system are more common among the
known targets of A-to-I RNA editing by ADARs [1]. Some
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notable examples include a number of glutamate-gated
ion channels, the voltage-gated Kv1.1 potassium channel,
the GABAA receptor and the serotonin 5-HT2C receptor. In
almost all cases, A-to-I editing occurs at precise and func-
tionally important locations in the protein, changing key
amino acid residues crucial for the protein function [2].
Table S1 [see Additional file 1] summarizes the recoding
of ADAR substrates by RNA editing, the amino acid posi-
tion, and the physiological changes in channel properties
and expression.
Glutamate-gated ion channels
A-to-I RNA editing of the glutamate-gated ion channels is
the most extensively studied [3]. Five subunits of the
glutamate receptor (GluR-B, GluR-C, GluR-D, GluR-5 and
GluR-6) are found to undergo ADAR-mediated RNA edit-
ing [1]. Currently, a total of 4 editing sites that result in
amino acid changes have been identified, namely gluta-
mate to arginine (Q/R), arginine to glycine (R/G), isoleu-
cine to valine (I/V), and tyrosine to cysteine (Y/C).
The first target of A-to-I RNA editing discovered in the
mammalian system was the AMPA GluR-B subunit
mRNA, in which a genomically encoded glutamine codon
(CAG) was changed to an arginine codon (CIG) at posi-
tion 607 [4]. This edited Q/R site, also found in the kain-
ate receptor subunits GluR-5 and -6 [4], resides in the
"pore loop region" of membrane segment 2 which deter-
mines the ion permeability of the glutamate channel [5].
Channels that contain the edited R form are less permea-
ble to calcium [6]. However, for GluR-6, multiple editing
at the Q/R, I/V and Y/C sites, located at positions 621, 567
and 571 respectively, may lead to higher calcium permea-
bility [7]. Editing of the glutamate-gated ion channels at
the R/G site changes an arginine (AGA) residue to glycine
(IGA), resulting in an enhanced rate of recovery from
receptor desensitization [8].
In addition to regulating the electrophysiology of the
channel, editing also plays a role in other aspects of chan-
nel functions, namely channel assembly, exit from the
endoplasmic reticulum and channel inhibition by endog-
enous substances. The edited GluR-BR isoforms mainly
exist as monomers in the endoplasmic reticulum (ER),
whereas unedited GluR-BQ isoforms have a higher pro-
pensity to tetramerize and be transported to the synaptic
membrane [9,10]. Thus, editing at the Q/R site will affect
the availability of functional channels at synapse. Editing
of the Q/R site in the GluR-5 and GluR-6 subunits affects
inhibition of the channel by membrane fatty acids such as
arachidonic acid and docosahexaenoic acid [11]. Kainate
receptors with only the edited isoforms are strongly inhib-
ited by these compounds, while inclusion of a single
unedited copy is sufficient to confer resistance to this inhi-
bition.
In most cases, editing is not 100% efficient and both the
edited and non-edited isoforms co-exist in the cell. An
interesting exception is editing of the Q/R site at the GluR-
B subunits. In transgenic mice, failure to edit at this site
leads to epileptic seizure and death within 3 weeks after
birth [12].
Voltage-gated Potassium channel
Bhalla et al [13] reported that the mRNA transcript of
human Kv1.1 undergoes A-to-I RNA editing, resulting in
an amino acid change from genomic isoleucine to valine
(GTT) [14]. As the hKv1.1 gene is intronless, its exon-to-
exon pairing forms the RNA duplex that is recognized by
ADAR2. The A-to-I RNA editing occurs specifically at posi-
tion 400 in the channel's sixth transmembrane segment
(S6), which lines the ion conducting pore. Electrophysiol-
ogy analysis shows that the edited hKv1.1 exhibits rapid
recovery from fast inactivation as compared to the wild
type channel.
Interaction of an inactivating particle with the pore of
hKv1.1 channel results in channel inactivation. The I-to-V
amino acid change may disrupt this interaction, resulting
in a faster recovery from inactivation [15]. Voltage-gated
potassium channel plays an important role in the repo-
larization phase of the action potential. Therefore,
changes in the inactivation kinetics will have an impact on
the duration and frequency of the action potential. The
faster recovery from inactivation shortens the duration of
each action potential and increases the frequency of
action potential [15]. To add to the complexity, potassium
channels exist as tetramers, and each channel may contain
different ratios of edited and unedited subunits. The phys-
iological significance of the different extent of editing on
the final properties of channel inactivation and the firing
pattern of a neuron has yet to be determined.
GABAA receptor
The isoleucine codon (ATA) of the α3 subunit of the
GABAA receptor is highly edited, resulting in a methionine
codon (ATI) in the adult rat, mouse and human brains
[16,17]. This I/M site resides in position 342 in the pre-
dicted third transmembrane domain of the α3 subunit.
Functional analyses revealed that editing of this mRNA
transcript results in GABAA receptors with smaller ampli-
tudes, slower activation, and faster deactivation compared
to the unedited receptor [17].
GABAA receptors are ligand-gated chloride channels, con-
sisting of 5 subunits – 2 α subunits, 2 β subunits, and
either a γ or δ subunit [18]. In the adult brain, activation
of the GABAA receptors causes an influx of chloride ions,
which produces an inhibitory current. However, during
development, activation of the GABAA receptors produces
an excitatory response, which is important for develop-Molecular Brain 2009, 2:13 http://www.molecularbrain.com/content/2/1/13
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ment of the nervous system circuitry [19]. Editing of the
α3 subunit is developmentally regulated – the edited
GABAA  receptors are expressed predominantly in the
mature adult brain while the unedited receptors are
mostly found in the developing brain [17]. Hence, RNA
editing may regulate the function of the GABAA receptors
during development – by allowing the expression of the
non-edited GABAA receptors at the early stages, which play
a crucial role in synaptic formation, followed by expres-
sion of the edited subunit in adulthood that is more
suited to the inhibitory functions of GABAA receptors in
action potentials.
Serotonin 2C receptor
The 2C subtype of serotonin receptor (5-HT2CR), a mem-
ber of the G protein-coupled receptor superfamily, under-
goes A-to-I RNA editing at five editing sites, named A, B, E
(C0), C and D [20], causing amino acid changes from iso-
leucine to valine (I/V) at positions 157 and 161, isoleu-
cine to methionine (I/M) at position 157, asparagine to
serine (N/S), asparagine to aspartate (N/D) and asparag-
ine to glycine (N/G) at position 159. Editing does not
occur simultaneously at all five sites, and the differential
combination of editing results in at least seven 5-HT2CR
protein isoforms in rats [20] and at least 12 in humans
[21]. Coincidentally, all five editing sites reside closely in
the second intracellular loop of the receptor [20], which is
responsible for its coupling to the G-protein [22]. Radio-
ligand binding and functional studies of the edited iso-
forms showed a reduction in G-protein coupling and a
lower level of constitutive activity, suggesting that RNA
editing may be a novel mechanism for regulating neuro-
nal excitability by stabilizing receptor signaling and
enhancing the signal to noise ratio at serotonergic syn-
apses [21].
Family of Adenosine Deaminases that Act on RNAs 
(ADARs)
Currently, three members of the ADAR family have been
discovered in mammals, namely ADAR1, ADAR2 and
ADAR3, according to the sequence of discovery. ADAR1
and ADAR2 were shown to be ubiquitously expressed,
with enzymatic targets identified mainly in the nervous
system while ADAR3 expression is restricted to brain and
has yet no known targets [3,23]. ADARs work by recogniz-
ing partial or complete double-stranded RNA duplexes
that are formed via base-pairing between the edited site
and the editing-site complementary sequence (ECS),
which is usually located in the downstream intron [24].
Although the mechanism of site-specific editing is incom-
pletely understood, at least two studies have provided
some insight into the roles of the multiple copies of dou-
ble-stranded RNA binding motif (dsRBM). The dsRBM is
a small motif of 75–85 amino acids, with the typical
βαββαβ topology that forms a four stranded β-sheet
packed against two α-helices [25]. ADAR1 contains three
dsRBM, and ADAR2 and ADAR3 each contains two
dsRBMs in the amino (N) -terminus.
Full-length ADAR2 is unable to edit a 15-base pair RNA
substrate harboring the R/G site of GluR-B, but this activ-
ity is restored when the N-terminal segment, including the
dsRBM1 was deleted [26]. Furthermore, addition of the N-
terminal segment in trans inhibits the recovery of editing
activity, supporting the hypothesis that dsRBM1 inhibits
the catalytic site of the enzyme. The study also implies that
a minimum length requirement for the duplex RNA sub-
strate exist, in order to engage both of the dsRBMs. Such a
limitation would therefore restrict the editing specificity
to RNA duplex structure of sufficient length. A second
study reveals that the two dsRBMs of ADAR2 recognize
different secondary structural elements of the RNA [27].
Via NMR-based model of the complex formed between
ADAR2 protein and RNA encoding the R/G site, it is
observed that while the dsRBM1 binds preferentially to
the loop regions, the dsRBM2 recognizes two bulges in the
stem region adjacent to the edited site (as shown in Figure
1). Therefore, recognition and binding of ADAR substrates
by dsRBMs is structurally-dependent and length sensitive.
In addition, multiple copies of dsRBMs and subtle amino
acid changes among the different dsRBMs could allow
preferential binding of ADAR family members to RNA
substrates with different secondary structures.
Substrate specificity could also be defined by the deami-
nase domain of ADAR. Protein chimeras, in which the
deaminase domains were exchanged between ADAR1 and
ADAR2, retained the substrate specificity of the donor's
deaminase domain [28]. Although the crystal structure of
ADAR2's deaminase domain has been resolved, and the
roles of zinc and inositol hexakisphosphate (IP6) as co-
factors have been elucidated [29], the mechanism by
which the catalytic site confers target specificity remains
unknown.
ADAR proteins show exclusive nuclear localization and
activity, with the exception of one splice variant of
ADAR1, and edit the primary transcripts before splicing
occurs [2]. While A-to-I editing in the coding region
potentiates the generation of multiple RNA and protein
isoforms from a single gene, editing in the untranslated
regions may impact on other aspects of RNA functions
such as splicing, mRNA stability and translation efficiency
[30]. For example, editing in the intron may introduce
alternative splice sites and could hence alter the reading
frame.
Regulation of ADAR activity by self-editing
Both the pre-mRNA and mRNA of rat ADAR2 are suscep-
tible to A-to-I editing, mediated by ADAR2 itself [30]. TheMolecular Brain 2009, 2:13 http://www.molecularbrain.com/content/2/1/13
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rADAR2 pre-mRNA self-editing occurs in intron 1 and
exon 2, which comprise the hotspot of this gene, at six dif-
ferent editing positions, namely -2, -1, +10, +14, +23, and
+24 [30,31]. Editing at position -1 in intron 1 converts an
adenosine-adenosine (AA) dinucleotide to adenosine-
inosine (AI), which mimics the canonical AG dinucle-
otides normally found at the 3' splice junction [30]. The
presence of AI thus acts as an alternative 3' splice acceptor
site, resulting in the retention of 47 nucleotides (nt) at
+28 position of exon 1. This generates a frameshift and a
truncated protein sequence with no editing activity, if
translation starts at the first initiator methionine residue.
Species differences is observed in the inclusion of 47-nt
isoform in the brain, with an expression level of approxi-
mately 80% in mouse brain, while only around 15% of
the ADAR2 transcripts in human brain has it [32]. In both
species, the expression of the self-edited 47-nt isoform is
more abundant in the brain than in the liver [32].
Alternatively, a downstream initiator methionine at
amino acid position 25 in rat ADAR2 could be used to
generate the functional protein for the self-edited iso-
forms [30]. However, in human ADAR2 proteins, the next
methionine occurs only at position 84, which lies in the
dsRBM1. Initiation of translation at this site may then
compromise the RNA binding capacity of the expressed
protein, and furthermore, may be inefficient and reduce
protein expression. Transgenic mice lacking ADAR2 self-
Model of the conformational changes during ADAR2-mediated RNA editing Figure 1
Model of the conformational changes during ADAR2-mediated RNA editing. The deaminase domain is represented 
by the blue box; double-strand RNA binding motif (dsRBM), by the yellow boxes. In the absence of RNA, ADAR2 protein is 
inactive because the N-terminal domain prevents the association of dsRBMII and catalytic domain with substrate. In the pres-
ence of RNA substrate with specific secondary elements and sufficient length, conformational change frees up the catalytic 
domain, and allows both dsRBM and catalytic domain to bind to RNA substrate, as well as activation of enzyme. After the 
edited site is converted from A (in red) to a G (in red) by ADAR2, the RNA substrate is released for translation. (Figure 
adapted from Macbeth et al [26].)Molecular Brain 2009, 2:13 http://www.molecularbrain.com/content/2/1/13
Page 5 of 11
(page number not for citation purposes)
editing express significantly higher levels of ADAR2,
accompanied by increase in the editing levels of various
ADAR2 substrates [33]. This implies that editing of its
own pre-mRNA may thus serve as a negative feedback
mechanism by which ADAR2 regulates its own expression
activity.
Regulation of ADAR activity by alternative splicing
The human ADAR2 gene consists of 14 exons, with exons
-2 and -1 located in the 5'-untranslated region (UTR) and
exons 9 and 10 in the 3'-UTR [32]. In addition to reten-
tion of 47-nt via self-editing, multiple variations are also
observed at the N-terminal via splicing, as indicated in
Figure 2. In humans, the alternative inclusion of exon 1a
adds 28 amino acids to the front of the commonly recog-
nized initiator methionine residue. In comparison, the
retention of exon 1b in mouse results in frame-shifting
and early truncation of the protein [32]. Although it is
proposed that alternative use of methionine in exon 1b
may still result in the production of a functional protein,
it is yet to be determined if the transcripts containing exon
1a or exon 1b could be expressed in vivo.
Maas and Gommans recently discovered a novel exon
(exon 0) of mammalian ADAR2 located 18 kb upstream
of exon 1, which extends the open reading frame by 49
amino acids [34]. Interestingly, the 49 amino acid exten-
sion harbors a sequence motif that is closely related to the
R-domain of ADAR3, where it has been shown to function
as a basic single-stranded RNA binding domain. Quanti-
tative expression analysis shows that expression of the
novel splice variant is tissue-specific, with the highest level
in the cerebellum. In addition, the strong sequence con-
servation of the R-domain between human and rodent
ADAR2 genes suggests a conserved function for this splice
isoform.
Alternative splicing of exon 2 in the mRNA transcript of
human ADAR2 could result in frame-shifting and an early
stop codon in exon 3 [35]. In addition, the inclusion of an
in-frame  Alu  sequence encoded by exon 5a in human
ADAR2 reduces its catalytic activity by 50% [36]. In com-
parison, use of an alternative 3' splice acceptor site in
intron 5 of mouse ADAR2 results in the inclusion of 30-nt
Alu sequence and relatively higher catalytic activity [30].
ADAR2 genomic structures for both human and mice Figure 2
ADAR2 genomic structures for both human and mice. Exons are represented by boxes; intron, by lines. Filled boxes 
are coding and open boxes are non-coding. # and * indicate the positions of potential initiator methionines and stop codons 
respectively. The grey box before exon 2 indicates the 47 nucleotide cassette, and A/G denotes the site of editing that creates 
the AG splice site. Alternatively spliced exons are indicated. The yellow box indicates the position of dsRBM, double stranded 
RNA binding domain while the green box indicates the position of catalytic domain. (Figure adapted from Slavov and Gardiner 
[32].)Molecular Brain 2009, 2:13 http://www.molecularbrain.com/content/2/1/13
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Furthermore, use of the alternative splice site in exon 9
leads to a deletion of 29 amino acids from the carboxyl-
terminal of human ADAR2 protein, resulting in a prema-
ture stop in exon 10. Such splicing event results in ADAR2
isoforms that have little editing activity on GluR-B mRNA
[33]. Splicing in the 3' UTR of both human and mouse
ADAR2 further contributes to the repertoire of ADAR2
proteins. Differential protein expression of C-terminal
splice isoforms, detected by western blot, implies that
such subtle splicing events could also play a role in regu-
lating the translation efficiency of ADAR2 [35].
Cross-talk among ADAR1, ADAR2 and ADAR3
ADAR1 and ADAR2 have been shown to function as
homodimer by both in vivo and in vitro experiments while
the endogenous dimer formation of ADAR3 is also
observed in mouse brain [14]. However, there is still con-
troversy regarding interaction between the different
ADARs to form heterodimers [14]. Overexpression of
ADAR1 is shown to inhibit the editing activity of ADAR2
in pediatric astrocytoma, and ADAR1 could co-immuno-
precipitate with ADAR2, suggesting a possible mechanism
of inhibition via sequestering ADAR2 by ADAR1 in a het-
erodimer formation [37].
Formation of heterodimers between ADAR splice iso-
forms is shown to influence the overall editing efficacy. A
reduction in RNA editing efficacy is observed in transgenic
Drosophila expressing both wild type and inactive ADAR
isoforms, which retains the binding to dsRNA substrates
[38]. Although the structural details of interaction
between two ADAR monomers are still unknown, the
crystal structure of structurally similar cytidine deaminase
APOBEC-1 homodimer has indicated that the active site
in each monomer is completed only with contribution
from the other partner [36]. Therefore, it is possible that a
heterodimer of ADAR1 and ADAR2 may result in a non-
functional enzyme that could neither edit ADAR1 nor
ADAR2 substrates. In addition, the combination of splice
variants of ADAR2 with low or no editing activities could
also exert dominant negative effect via the formation of
heterodimer with the wild type enzyme.
Furthermore, ADAR3 is observed to inhibit the activities
of ADAR1 and ADAR2 in vitro, suggesting a possible role
of ADAR3 in regulating the editing activity mediated by
ADAR1 and ADAR2 [39].
Subcellular localization of ADAR1 and ADAR2
Subcellular localization of ADAR1 and ADAR2 proteins
offers another intriguing aspect on the regulation of A-to-
I editing efficacy. ADAR1 proteins, which shuttle between
the nucleus and cytoplasm, contain a nuclear localization
signal (NLS) located in the dsRBM3 [40] and a putative
nuclear export signal (NES) in the N-terminal [41]. On
the other hand, the activity of ADAR2 is restricted to the
nucleus due to the single NLS in its N-terminal domain
[42].
It is demonstrated by Desterro and co-workers that both
ADAR1 and ADAR2 could be transiently sequestered into
the nucleolus, a subnuclear region where transcription of
ribosomal RNA (rRNA) occurs [41]. Local accumulation
of small nucleolar RNAs (snoRNAs) in the nucleolus may
be responsible for the tethering of ADAR1 and ADAR2,
due to interaction between these dsRNA structures with
the dsRBD of ADAR. Enhanced translocation of ADAR2 to
the nucleoplasm occurs upon the inhibition of rRNA syn-
thesis or the presence of editing substrates in the nucleo-
plasm, which correlates with increased editing efficacy
[42]. Such a model would therefore suggest that the edit-
ing substrates and snoRNAs compete for binding to the
ADAR proteins. Hence, with accumulation of specific edit-
ing substrates in the nucleoplasm, the balance shifts and
ADAR proteins are recruited to the nucleoplasm for A-to-
I editing.
Developmental regulation of RNA editing
Editing of mRNA transcripts by ADAR enzymes is critical
for normal life and development, as observed from the
knockout mice that are deficient in either ADAR1 or
ADAR2. ADAR2-/- knockout mice develop normally, but
are prone to early onset of epilepsy and die within three
weeks of birth. Underediting of the Q/R site in the GluR-
B transcripts appears to be the underlying reason for the
epileptic seizures, which could be rescued by introducing
an edited version of GluR-B gene into the ADAR2-/- mice
[43]. The deletion of ADAR1 in mice is embryonically
lethal, and mice die between E11.5 and 12.5, as the mice
develop a severe liver defect that involves cells of both the
hematopoietic and hepatic lineages. Thus, ADAR1
appears to have a critical function in non-nervous tissues,
which is likely to affect transcript editing [44].
Developmental analysis of known RNA editing substrates
shows that editing of certain sites is regulated during the
development of the brain. These would include mRNA
transcripts of the AMPA and kainate members of the
glutamate receptor family – GluR-B, GluR-5 & GluR-6
[33], the serotonin 5-HT2C receptor [45], the α3 subunit of
GABAA receptor [16,17], and ADAR2 itself [30]. Stimula-
tion of calcium-permeable AMPA receptors steers differ-
entiation of neural progenitor cells (NPCs) preferentially
to neuronal cells, and promotes dendritic arborization.
Overexpression of ADAR2 in NPCs results in Q/R editing
and expression of calcium-impermeable AMPA receptors,
which prevents AMPA-mediated differentiation, suggest-
ing a physiological role for the Q/R editing process and
the importance of unedited AMPA receptor subunits in
neurogenesis [46]. While transition to edited AMPA corre-Molecular Brain 2009, 2:13 http://www.molecularbrain.com/content/2/1/13
Page 7 of 11
(page number not for citation purposes)
lates with the overexpression of ADAR2, the exact mecha-
nism and/or factors involved in regulation of RNA editing
remain to be elucidated. Two studies tried to establish a
correlation between ADAR mRNA expression level and
editing frequency of 5-HT2CR and GluR-B transcripts
[45,47], but concluded that changes in expression level
only is an insufficient model.
In the rat brain, both developmental and regional regula-
tion of ADAR2 mRNA expression and splicing are
observed [47]. Two splice variants of ADAR2, differing by
the addition of a 30-nt Alu cassette, colocalize throughout
the brain. While expression in the thalamic nuclei is the
highest, the Alu-containing splice variant is more abun-
dant overall. Interestingly, the expression of ADAR2
mRNA does not correspond temporally or spatially with
its physiological substrates, GluR-B and 5-HT2CR. A sepa-
rate study by Hang et al finds that while expression level
of ADAR2 mRNA markedly increases, that of ADAR1
mRNA remains constant during development [45]. Dur-
ing the embryonic period, ADAR2 pre-mRNA is unedited,
but the number of edited sites and editing frequency
increase after birth, suggesting that expression of edited
ADAR2 may be significant to normal brain development.
In addition, expression of ADAR1 and ADAR2 does not
correspond with editing frequencies of specific target sites
in the 5-HT2CR mRNA. ADAR1 edits the A- and B-sites in
5-HT2CR mRNA [48], while ADAR2 mediates editing of
sites C and D [49]. Although the editing efficacies mark-
edly increase during development, ADAR1 mRNA expres-
sion remains constant, suggesting that other factors may
cooperate with ADAR1 such as RNA helicase [49,50].
Three models are proposed to help explain the mecha-
nism behind the developmental increase in RNA editing
[33]. First, ADAR1 and ADAR2 could be regulated at the
post-transcriptional level such as protein modification or
compartmentalization, which would enhance enzyme
activity or its access to substrates. Second, the editing
machinery may need a cofactor, which could synergisti-
cally enhance the actions of ADAR enzymes. Some poten-
tial candidates include the zinc ion, which coordinates
and allows binding of ADAR2 to its pre-mRNA substrates,
or the IP6, an inositol polyphosphate that binds and fills
an extremely basic cavity in ADAR2 [29]. Third, access of
ADAR enzymes to the editing sites may be controlled neg-
atively by a competitive inhibitor. The 5-HT2CR mRNA
has significant sequence complementarity with a small
nucleolar RNA, MBII-52, which specifically inhibits nucle-
olar editing [51], and the relative expression of MBII-52
may shift the balance of editing by trafficking or seques-
tering transcripts to specific compartments [52].
Hence, although the mRNA level of ADAR1 and ADAR2
may play critical physiological roles in the brain and
peripheral tissues, changes in the expression of these
enzymes alone could not account for the developmental
regulation of RNA editing observed in the brain.
Activity-dependent RNA editing
RNA editing can be regulated by changes in metabolic
activity, such as glucose concentration or serotonin level.
Gan et al [53] reported an upregulation of ADAR2 tran-
scripts and an increase in ADAR2-mediated editing of the
GluR-B subunits in pancreatic β-islet cells exposed to
physiological concentration of glucose, and the reverse
occurred when the glucose concentration was decreased.
Transient forebrain ischemia is caused by disruption of
blood flow to the brain, causing a highly selective pattern
of neuronal loss in the nervous system due to entry of
toxic zinc and calcium ions into vulnerable neurons. In
the setting of ischemia, heightened glycolysis could per-
turb glucose concentrations, leading to altered ADAR2
activity and editing. It is shown that forebrain ischemia in
adult rats selectively reduces ADAR2 enzyme expression,
and hence, disrupts editing of the Q/R site in GluR-B in
vulnerable neurons [54]. Editing of this site determines
the vulnerability of neurons in the rat hippocampus to
forebrain ischemia. Expression of exogenous ADAR2 gene
or a constitutively active CREB, which induces expression
of endogenous ADAR2, results in recovery of Q/R editing
in GluR-B and protection of vulnerable neurons in the rat
hippocampus from this injury. In addition, ADAR2 gene
silencing leads to degeneration of ischemia-insensitive
neurons, and direct introduction of mutated gene, GluR-
BQ607R prevents neuronal degeneration.
As mentioned above, the 5-HT2CR pre-mRNA is edited at
five closely-spaced adenosine residues located within the
second intracellular domain of the receptor. The efficacy
of editing at these sites is dependent on the serotonin
level. Significantly decreased levels of editing at the C- and
E- sites of 5-HT2CR mRNA are observed in serotonin-
depleted mice, leading to the expression of receptors with
higher sensitivity to serotonin [55]. However, treatment
with a 5-HT2A/2C agonist increases the editing frequency at
the E-site and the expression of receptor that activates G-
proteins least efficiently. Hence, changes in the editing
status of 5-HT2CR pre-mRNA could alter synaptic receptor
activation and signaling bidirectionally depending on the
receptor isoforms present.
Through the understanding of regulation of RNA editing
in the physiological conditions, we could extend this
knowledge into the study of pathophysiological condi-
tions, and new treatment strategies that specifically target
injured areas in the nervous system.Molecular Brain 2009, 2:13 http://www.molecularbrain.com/content/2/1/13
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Consequences of RNA editing dysregulation
Dysregulation of RNA editing has been linked to many
human diseases and recent studies have shown its impor-
tance in cancer [56]. Patients with glioblastoma multi-
forme (GBMs) have a reduction in both ADAR2 activity
and editing of the GluR-B mRNA at the Q/R site [57]. Neo-
plasm of glial cells represents the most common tumors
of the CNS with GBMs being the most malignant [56].
Ishiuchi et al demonstrated that the Ca2+-permeable non-
edited GluR-BQ promotes migration and proliferation of
the gliobastomas, thus driving invasion and abnormal
growth [58]. Expression of the edited GluR-BR, which is
less permeable to calcium ion, prevents cell migration and
induces cell death. Therefore, the Q/R site of the GluR-B is
necessary for regulating migration of glioblastoma cells.
In a separate study, a correlation between reduction of
ADAR2 editing activity and grade of astrocytomas is
observed in children [37]. The authors also found that res-
toration of the ADAR2 editing activity in astrocytoma cell
lines inhibit cell migration and proliferation. Using both
bioinformatic approach and direct sequencing, considera-
ble global hypoediting of Alu  repetitive elements is
observed in various tumors of the brain, prostate, lung,
kidney, and testis [59]. Reduction of ADAR3 is found to
correlate with the malignancy of GBMs. In addition, the
mRNA levels of all 3 members of the ADAR family are
reduced in brain tumors, most significantly in ADAR3.
Overexpression of ADAR1 and ADAR2 in GBM cell line
results in a decreased proliferation rate, suggesting that
reduced A-to-I editing in brain tumors is involved in the
pathogenesis of cancer [59].
Dysregulation of epigenetic mechanisms is recently
shown to play a central role in pathogenesis of cancer.
Interestingly, A-to-I RNA editing may serve as an addi-
tional epigenetic mechanism relevant to cancer develop-
ment and progression. In the mammalian nervous
system, ion channels are common targets of ADARs-medi-
ated editing. Ion channels play an important role in con-
trolling cell cycle and proliferation and alteration of their
activities may facilitate cancer progression [60]. However,
as neoplastic cells are genetically unstable and exhibit
numerous altered biological pathways, it is debatable as
to whether reduction in editing of ADARs substrates is the
cause or just a consequence of tumor progression.
Epilepsy is a neurological disorder characterized by recur-
rent, unprovoked seizures, due to neuronal hyperexcita-
bility. The epileptic phenotypes observed in GluR-B
editing-deficient mice are most profound and the severity
of seizure activity correlates directly with the degree of
impairment in editing of the Q/R position [61]. Although
the molecular mechanism for epileptogenesis in these
transgenic mice has not been elucidated, pre-editing of
the GluR-B mRNA through genomic mutation rescues the
seizure phenotype, suggesting that it is the changes in the
AMPA channel properties are the cause. A conditional
mouse mutant where GluR-B editing is inactivated post-
natally in selected forebrain regions supports the notion
that unedited GluR-B directly causes neuron hyperexcita-
bility, as editing deficiency in adult mice induces seizures
with similarity to human temporal lobe epilepsy [62]. In
contrast, elimination of GluR-B, which also results in
Ca2+-permeable AMPA receptors, does not elicit an epilep-
tic phenotype in mice. Underediting of the Q/R site in
GluR-B is critical because it not only determines AMPA
receptors' Ca2+  permeability, but also regulates gating
kinetics, channel conductance, and channel assembly and
trafficking. Epilepsy associated with GBM might also be
linked to a decrease in GluR-B Q/R site editing [57].
Amyotrophic lateral sclerosis (ALS) is a progressive neuro-
degenerative disease of the motor neurons, resulting in
progressive symptoms of muscle weakness, muscle atro-
phy, spasticity and eventually paralysis. Glutamate excito-
toxicity appears to contribute to the pathology of sporadic
ALS, whereby increase in glutamate levels suggest that
prolonged activation of glutamate-gated ion channels
might lead to excessive Ca2+ influx and neuronal death.
The contribution of excessive Ca2+ influx through gluta-
mate receptors to the death of motor neurons suggest that
RNA editing might play a role in ALS. Editing at the Q/R
position in GluR-B of spinal motor neurons from ALS
patients were severely decreased, ranging from 62–100%,
whereas all normal control cells showed 100% editing
[63]. However, this deficiency in editing was not detected
in motor neurons of rats transgenic for mutant human
SOD1 (an animal model for familial ALS) or in patients
with non-ALS motor neuron diseases, indicating that
abnormal editing may be a contributory cause of neuro-
nal death specifically in sporadic ALS. Again, it is not
known when during the disease progression this impair-
ment in editing arises or if it might be a causative event
during the onset of ALS. Furthermore, this deficiency is
only observed in spinal motor neurons, whereas upper
motor neurons, which also degenerate in ALS, showed
unaltered editing levels of GluR-B. This means that a
defect in the Q/R site editing cannot be the sole mecha-
nism responsible for the demise of the motor neurons. A
recent genetic mouse model, whereby GluR-B subunits
express the residue asparagine (N) at the Q/R position,
results in channels with modestly increased Ca2+ permea-
bility and late-onset motor neuron disease resembling the
pathological changes observed in sporadic ALS [64]. Sub-
stantial increase in Ca2+ permeability of the AMPA recep-
tors in principal neurons leads to early lethality
precluding the observation of late-onset degenerative dis-
eases. In addition, the GluR-BN mutation accelerates dis-
ease progression and decrease survival in the backgroundMolecular Brain 2009, 2:13 http://www.molecularbrain.com/content/2/1/13
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of SOD1G93A mutation, which has been linked to cases of
familial ALS.
Clinical relevance of RNA editing: 5-HT2C receptor
The involvement of serotonin in psychiatric disorders
such as schizophrenia, depression and anxiety has been
based largely on pharmacological studies [65,66], while
its action mechanism remains to be elucidated. Several
studies suggest that editing of 5-HT2CR mRNA is involved
in the pathophysiology of psychotic disorders, and may
also regulate efficacy of hallucinogenic and antipsychotic
drugs on the serotonin 5-HT2C receptors [21,55,67]. A
marked reduction in sensitivity to LSD and atypical antip-
sychotic drugs is observed in the fully edited human 5-
HT2CR (VGV) isoform, which suggests a role for edited 5-
HT2CR in the etiology and pharmacotherapy of schizo-
phrenia [21]. Cohort studies of depressed suicide victims
and schizophrenic patients observe altered editing of 5-
HT2CR pre-mRNA in the prefrontal cortices, but caution
must be taken when interpreting these results. For
instance, no alterations of editing patterns is observed in
three independent studies conducted regarding schizo-
phrenia [21,67,68], while only the report by Sodhi et al
[69] claims to observe significant decrease in editing of
the B-site of 5-HT2CR mRNA. This discrepancy could be
due to limitations of such studies, namely the small sam-
ple size, methodological differences, and medication his-
tory of subjects. Interestingly, two separate studies by
Niswender et al, and Iwamoto and Kato report increased
RNA editing efficacy at the A-site of 5-HT2CR mRNA in
depressed patients. Furthermore, Gurevich et al observe a
significant increased at the E-site as well [55], which it also
reported in a rat model of depression, and could be
reverted through treatment with serotonin-selective
reuptake blocker fluoxetine [67].
Among inbred strains of mice, the pattern of 5-HT2CR
editing is found to be significantly different [70]. In
C57BL/6 and 129SV mice, more than 80% of forebrain
neocortical 5-HT2CR mRNAs are edited in at least one site
while in the BALB/c strain, about 80% of the serotonin 2C
receptors are not edited at all. Furthermore, the strains
also differed in alteration of the editing pattern against
acute stress or chronic treatment of fluoxetine. These
observations imply that editing responsiveness to stress
and medication is modulated by genetic background, as
well as behavioral state. Thus, development of animal
models may provide more robust insights into relation-
ships between editing of serotonin 2C receptors and men-
tal disorders as compared to association studies using
postmortem brains.
A-to-I editing of 5-HT2CR mRNA mediated by ADARs may
be involved in mental disorders, and the increased under-
standing of the editing mechanism and target spectrum
can explain some of the phenotypic features that result
from RNA editing deficiency or hyperactivity. Owing to
the functional implications of RNA editing, the ADAR
enzymes may be targets for the pharmacological treat-
ment of diseases of the central nervous system, such as
depression, epilepsy, and schizophrenia.
Summary and outlook
RNA editing was once considered a rare peculiarity, and
most studies in the mammalian brain have historically
focused on just two editing targets, glutamate-gated ion
channels and serotonin 2C receptors. However, a growing
list of other brain editing targets has begun to overturn
this initially limited view. RNA editing generates a diverse
repertoire of proteins from a small fixed pool of genes that
is able to fine tune and response dynamically to rapid
changes in the nervous system. Dysregulation of RNA
editing results in irregular responses in the nervous sys-
tem, some of which could even prove fatal [43]. Current
understanding of the mechanisms underlying the regula-
tion of RNA editing is still poorly understood and any cor-
relations are still hypothetical. This review attempts to
provide an insight to existing models of explanation – reg-
ulation of ADAR expression and activity by self-editing,
alternative splicing and cross-talk among ADAR family
members; developmental and activity-dependent regula-
tion of A-to-I editing through environmental cues. Besides
identifying new targets of A-to-I editing through bioinfor-
matics, focus should be redirected to methodically exam-
ining the regulation of editing, as it seems to contribute
significantly to both the physiological and pathophysio-
logical conditions observed in the mammalian nervous
system.
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